EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Therapeutic equivalence and switching between biosimilar and reference insulins: A systematic review and meta‐analysis of randomised controlled trials

Xiaoxuan Xing, Lingyi Zhao, Ke Wang, Zhizhou Wang, Lan Zhang, Xianzhe Dong iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70328 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Xiaoxuan Xing und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Hypoglycemic Agents, Drug Substitution, Insulin. Die Arbeit nennt 53 Literaturangaben. Gefördert von: National Healthcare Security Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To comprehensively evaluate the therapeutic equivalence and switching between biosimilar insulins and reference insulins in efficacy, safety and immunogenicity in diabetes. Materials and Methods MEDLINE (via PubMed), Embase and Cochrane Library were searched (inception to March 2025) for randomised controlled trials (RCTs) employing two designs: (1) therapeutic equivalence trials directly compared biosimilar insulins vs. reference insulins; (2) switching trials where participants initially received reference insulin during a run‐in period and were then randomised to either switch to biosimilar insulins or continue reference insulins. Outcomes included change in glycated hemoglobin (HbA1c) (%), achievement of HbA1c < 7%, change in fasting blood glucose (FBG), adverse events and immunogenicity. Heterogeneity was examined with I 2 statistics. Data were pooled using mean differences (MDs) for continuous variables and odds ratios (ORs) for binary outcomes with 95% confidence intervals (CIs).

Results

A total of 25 RCTs involving 10 617 patients were included: equivalence analysis of 16 RCTs ( n = 6548 patients) and switching analysis of nine RCTs ( n = 4069 patients). No significant differences were found for change in HbA1c (equivalence: MD 0.01%, 95% CI −0.04, 0.06; switching: MD −0.01%, 95% CI −0.06, 0.05), the proportion achieving HbA1c

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsHypoglycemic AgentsDrug SubstitutionInsulinDiabetes MellitusHumansRandomized Controlled Trials as TopicGlycated HemoglobinTherapeutic EquivalencyBlood Glucose

Stichwörter der Autor:innen

biosimilar insulineffectivenessrandomised trialsystematic review

Substanzen

Biosimilar PharmaceuticalsHypoglycemic AgentsGlycated HemoglobinBlood GlucoseInsulinhemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, China.

ORCID-Profile: Xianzhe Dong

Förderung

  • National Healthcare Security Administration

Zitieren

APA

Xing, X., Zhao, L., Wang, K., Wang, Z., Zhang, L., & Dong, X. (2026). Therapeutic equivalence and switching between biosimilar and reference insulins: A systematic review and meta‐analysis of randomised controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70328

Vancouver

Xing X, Zhao L, Wang K, Wang Z, Zhang L, Dong X. Therapeutic equivalence and switching between biosimilar and reference insulins: A systematic review and meta‐analysis of randomised controlled trials. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70328

BibTeX
@article{Xing2026,
  author = {Xing, Xiaoxuan and Zhao, Lingyi and Wang, Ke and Wang, Zhizhou and Zhang, Lan and Dong, Xianzhe},
  title = {Therapeutic equivalence and switching between biosimilar and reference insulins: A systematic review and meta‐analysis of randomised controlled trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70328}
}
Kostenlos starten →